Literature DB >> 5925313

Studies of PPLO infection. II. The neurotoxin of Mycoplasma neurolyticum.

L Thomas, F Aleu, M W Bitensky, M Davidson, B Gesner.   

Abstract

Rolling disease has been produced and studied in rats and mice, using the exotoxin of the A strain of Mycoplasma neurolyticum. The primary lesion of the brain consists of spongiform degeneration, associated with vesicle formation in the cortex and underlying white matter of the cerebral hemispheres, and in the molecular layer of the cerebellum. The brains of animals surviving 2 days or longer show extensive necrotizing lesions resembling ischemic necrosis, in both cerebral hemispheres. The brains of rats and mice with rolling disease become deeply stained by intraperitoneally injected trypan blue, indicating early disruption of the blood brain barrier. The toxin appears to be a thermolabile protein with a molecular weight exceeding 200,000. It is only active when injected by vein, and causes no disease when injected intracerebrally, intraperitoneally or subcutaneously, suggesting the existence of specific receptors within the vascular bed of the central nervous system. Protection is afforded by rabbit antibody against the toxin, but only when antibody is injected within less than 3 min after intravenous injection of toxin, indicating rapid fixation to receptors in the brain. The toxin is inactivated by incubation for 10 min at 37 degrees C with suspensions of the sedimentable component of normal brain. The inactivating factor in brain sediment is very thermostable, not affected by trypsin, and eliminated by treatment with periodate. Similar inactivation of toxin is demonstrable with water-soluble gangliosides of brain. A theoretical concept to explain the action of the toxin is proposed.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5925313      PMCID: PMC2138330          DOI: 10.1084/jem.124.6.1067

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  11 in total

1.  MYCOPLASMA SPECIES IDENTIFICATION BASED UPON GROWTH INHIBITION BY SPECIFIC ANTISERA.

Authors:  W A CLYDE
Journal:  J Immunol       Date:  1964-06       Impact factor: 5.422

2.  Growth on artificial medium of an agent associated with atypical pneumonia and its identification as a PPLO.

Authors:  R M CHANOCK; L HAYFLICK; M F BARILE
Journal:  Proc Natl Acad Sci U S A       Date:  1962-01-15       Impact factor: 11.205

3.  The fixation of tetanus toxin by ganglioside.

Authors:  W E VAN HEYNINGEN; P A MILLER
Journal:  J Gen Microbiol       Date:  1961-01

4.  Liver and brain mitochondria.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1957-11       Impact factor: 3.857

5.  IDENTIFICATION OF THE FILTRABLE, TRANSMISSIBLE NEUROLYTIC AGENT ISOLATED FROM TOXOPLASMA-INFECTED TISSUE AS A NEW PLEUROPNEUMONIA-LIKE MICROBE.

Authors:  A B Sabin
Journal:  Science       Date:  1938-12-16       Impact factor: 47.728

6.  ISOLATION OF A FILTRABLE, TRANSMISSIBLE AGENT WITH "NEUROLYTI" PROPERTIES FROM TOXOPLASMA-INFECTED TISSUES.

Authors:  A B Sabin
Journal:  Science       Date:  1938-08-26       Impact factor: 47.728

7.  Sialic acid binding sites: role in hemagglutination by Mycoplasma gallisepticum.

Authors:  B Gesner; L Thomas
Journal:  Science       Date:  1966-02-04       Impact factor: 47.728

8.  PRODUCTION AND BIOLOGICAL CHARACTERISTICS OF AN EXTRACELLULAR NEUROTOXIN FROM MYCOPLASMA NEUROLYTICUM.

Authors:  J G TULLY
Journal:  J Bacteriol       Date:  1964-08       Impact factor: 3.490

9.  Studies of PPLO infection. I. The production of cerebral polyarteritis by Mycoplasma gallisepticum in turkeys; the neurotoxic property of the Mycoplasma.

Authors:  L Thomas; M Davidson; R T McCluskey
Journal:  J Exp Med       Date:  1966-05-01       Impact factor: 14.307

10.  Studies of PPLO infection. 3. Electron microscopic study of brain lesions caused by Mycoplasma neurolyticum toxin.

Authors:  F Aleu; L Thomas
Journal:  J Exp Med       Date:  1966-12-01       Impact factor: 14.307

View more
  16 in total

1.  Mycoplasma gallisepticum infection in mice and cynomolgus monkeys. A histologic, immunofluorescence, and electron microscopic study of the heart.

Authors:  S C Sun; R S Sohal; K C Chu; H L Colcolough; E Leiderman; G E Burch
Journal:  Am J Pathol       Date:  1968-12       Impact factor: 4.307

2.  Mycoplasma pneumoniae protein involved in the antibody response in human infection.

Authors:  S Räisänen; J I Suni; A Vaheri
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

3.  Mycoplasma taxonomy studiedy electrophoresis of cell proteins.

Authors:  S Razin
Journal:  J Bacteriol       Date:  1968-09       Impact factor: 3.490

4.  Central nervous system complications of Mycoplasma pneumoniae.

Authors:  G Decaux; M Szyper; M Ectors; A Cornil; L Franken
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-10       Impact factor: 10.154

5.  Occlusion of brain capillaries by endothelial swelling in mycoplasma infections.

Authors:  E E Manuelidis; L Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1973-03       Impact factor: 11.205

6.  Mycoplasma pneumoniae infection and neurological disease.

Authors:  N H Thomas; J E Collins; S A Robb; R O Robinson
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

Review 7.  Mycoplasma pneumoniae: nervous system complications in childhood and review of the literature.

Authors:  Uluç Yiş; Semra Hiz Kurul; Handan Cakmakçi; Eray Dirik
Journal:  Eur J Pediatr       Date:  2008-05-28       Impact factor: 3.183

8.  Immunological response of rodents to murine mycoplasmas.

Authors:  B C Cole; L Golightly-Rowland; J R Ward; B B Wiley
Journal:  Infect Immun       Date:  1970-10       Impact factor: 3.441

9.  Growth and Pathogenesis of Mycoplasma mycoides var. capri in Chicken Embryo Tracheal Organ Cultures.

Authors:  J D Cherry; D Taylor-Robinson
Journal:  Infect Immun       Date:  1970-10       Impact factor: 3.441

Review 10.  Human diseases associated with mycoplasms. With an appendix on simple culture techniques.

Authors:  H J Harwock; G M Kalmanson; L B Guze
Journal:  Calif Med       Date:  1972-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.